Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
- Author
- PROPPER, D. J1 ; BRAYBROOKE, J. P1 ; LEVITT, N. C1 ; O'BYRNE, K1 ; CHRISTODOULOS, K1 ; HAN, C1 ; TALBOT, D. C1 ; GANESAN, T. S1 ; HARRIS, A. L1
[1] ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom - Source
British journal of cancer. 2000, Vol 82, Num 11, pp 1759-1763 ; ref : 26 ref
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Agent alkylant Anticancéreux Antihormone Antioestrogène Association médicamenteuse Carmustine Chimiothérapie Cisplatine Composé non stéroïde Dacarbazine Essai clinique phase II Homme Mélanome Nitrosourées Peau Platine II Complexe Pronostic Protocole thérapeutique Résistance traitement Stade avancé Tamoxifène Traitement Deuxième intention Protocole Dartmouth Peau pathologie Tumeur maligne
- Keyword (en)
- Alkylating agent Antineoplastic agent Antihormone Antiestrogen Drug combination Carmustine Chemotherapy Cisplatin Non steroid compound Dacarbazine Phase II trial Human Melanoma Nitrosoureas Skin Platinum II Complexes Prognosis Therapeutic protocol Negative therapeutic reaction Advanced stage Tamoxifene Treatment Skin disease Malignant tumor
- Keyword (es)
- Agente alquilante Anticanceroso Antihormona Antiestrógeno Asociación medicamentosa Carmustina Quimioterapia Cisplatino Compuesto no esteroide Dacarbazina Ensayo clínico fase II Hombre Melanoma Nitrosoureas Piel Platino II Complejo Pronóstico Protocolo terapéutico Resistencia al tratamiento terapeútico Estadio avanzado Tamoxifeno Tratamiento Piel patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1390832
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1054/bjoc.2000.1141 
https://dx.doi.org/10.1054/bjoc.2000.1141
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1054\/bjoc.2000.1141\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1759\";s:8:\"\u0000*\u0000epage\";s:4:\"1763\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PROPPER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"D. J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"BRAYBROOKE, J. P\";i:1;s:12:\"LEVITT, N. C\";i:2;s:10:\"O'BYRNE, K\";i:3;s:16:\"CHRISTODOULOS, K\";i:4;s:6:\"HAN, C\";i:5;s:12:\"TALBOT, D. C\";i:6;s:13:\"GANESAN, T. S\";i:7;s:12:\"HARRIS, A. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1054\/bjoc.2000.1141\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1759\";s:8:\"\u0000*\u0000epage\";s:4:\"1763\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PROPPER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"D. J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"BRAYBROOKE, J. P\";i:1;s:12:\"LEVITT, N. C\";i:2;s:10:\"O'BYRNE, K\";i:3;s:16:\"CHRISTODOULOS, K\";i:4;s:6:\"HAN, C\";i:5;s:12:\"TALBOT, D. C\";i:6;s:13:\"GANESAN, T. S\";i:7;s:12:\"HARRIS, A. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1054\/bjoc.2000.1141\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1054\/bjoc.2000.1141\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1759\";s:8:\"\u0000*\u0000epage\";s:4:\"1763\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PROPPER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"D. J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"BRAYBROOKE, J. P\";i:1;s:12:\"LEVITT, N. C\";i:2;s:10:\"O'BYRNE, K\";i:3;s:16:\"CHRISTODOULOS, K\";i:4;s:6:\"HAN, C\";i:5;s:12:\"TALBOT, D. C\";i:6;s:13:\"GANESAN, T. S\";i:7;s:12:\"HARRIS, A. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1054\/bjoc.2000.1141\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1759\";s:8:\"\u0000*\u0000epage\";s:4:\"1763\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PROPPER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"D. J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"BRAYBROOKE, J. P\";i:1;s:12:\"LEVITT, N. C\";i:2;s:10:\"O'BYRNE, K\";i:3;s:16:\"CHRISTODOULOS, K\";i:4;s:6:\"HAN, C\";i:5;s:12:\"TALBOT, D. C\";i:6;s:13:\"GANESAN, T. S\";i:7;s:12:\"HARRIS, A. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1054\/bjoc.2000.1141\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1759\";s:8:\"\u0000*\u0000epage\";s:4:\"1763\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PROPPER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"D. J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"BRAYBROOKE, J. P\";i:1;s:12:\"LEVITT, N. C\";i:2;s:10:\"O'BYRNE, K\";i:3;s:16:\"CHRISTODOULOS, K\";i:4;s:6:\"HAN, C\";i:5;s:12:\"TALBOT, D. C\";i:6;s:13:\"GANESAN, T. S\";i:7;s:12:\"HARRIS, A. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
